clinical trial tirzepatide Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in practice Tirzepatide cuts diabetes risk by

Curcumin, an anti-inflammatory compound found in turmeric, has been shown to increase secretion of GLP-1 and support weight loss and glucose control for those with type 2 diabetes

N Engl J Med 2023;388:117-27.ArticlePubMed 50

The rationale is usually "I want to avoid the nausea spike on injection day." The pharmacokinetic reality: splitting the dose does not reduce peak plasma concentration at steady state

What guidelines and real-world practice say Despite the lack of direct trials, major guidelines support: Using the lowest effective dose Shared decision-making Individualised plans In real-world practice, many clinicians: Use a maintenance phase Reduce dose gradually Monitor appetite, weight stability, and wellbeing Adjust based on how the person feels, not just the scales This approach is not because we have perfect data, but because it aligns with physiology, patient experience, and common sense

About 11% of U.S

Older adults using semaglutide should be particularly cautious and discuss this risk with their healthcare provider before starting treatment